IGFBP2 and endometrial cancer: Both the mTOR inhibitor RAD001 and the AKT inhibitor terameprocol (M4N) downregulated IGFBP2 expression in endometrial cancer cells by targeting the Sp1 transcription factor, resulting in synergistic inhibition of tumor growth (33).